Latest News

  • Alkermes to Host Conference Call to Discuss First Quarter 2021 Financial Results Read More
  • Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society Read More
  • Alkermes Announces Clinical Trial Collaboration and Supply Agreement With MSD to Evaluate Nemvaleukin Alfa in Combination With KEYTRUDA® in Patients With Platinum-Resistant Ovarian Cancer Read More
  • Alkermes to Take Part in Stifel's 3rd Annual CNS Day Read More

Investors